Prescribing information

 

Nurse support with pre-initiation tests prior to treatment with MAYZENT.

About the MayzentConnect nurses

Our MayzentConnect nurse team have experience caring for a wide range of patients, including patients with MS, and have in‑depth knowledge of MAYZENT. Once MAYZENT has been prescribed, our nurse team can provide pre-initiation tests, first-dose observation and ongoing monitoring.

How do MayzentConnect nurses support with pre-initiation tests required by your service prior to treatment with MAYZENT?

A MayzentConnect nurse can carry out any necessary pre-initiation tests prior to initiating treatment with MAYZENT.

These include:1

Collection of blood samples for baseline tests (including the metaboliser status genotype test)

Baseline ECG

Pregnancy test if required*

 

These are not all of the required pre-initiation tests. For detailed information on the prescribing and use of MAYZENT, please refer to the Summary of Product Characteristics (SmPC).

These tests will be carried out in the comfort of the patient’s place of choice, at a suitable date and time.

For more information on any aspects of MayzentConnect, ask your Novartis Representative.

 

*Women of childbearing potential: Due to risk for the foetus, siponimod is contraindicated during pregnancy and in women of childbearing potential not using effective contraception. Before initiation of treatment, women of childbearing potential must be informed of this risk to the foetus, must have a negative pregnancy test and must use effective contraception during treatment and for at least 10 days after treatment discontinuation. MAYZENT should not be used during breast-feeding.

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

ECG, electrocardiogram; SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2022 | 153212
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]